Scholar Rock Holding Corp
apitegromab
spinal muscular atrophy (SMA)
Date
TBD
Advisory committee · Date TBD estimated
What's at stake
An FDA advisory committee reviews apitegromab for spinal muscular atrophy (SMA) around Date TBD. The panel's public vote often front-runs the agency's final verdict — and the share price.
Primary source
· SEC 8-K
verified 14h ago
“A meeting between FDA and Catalent Indiana occurred early in the first quarter of 2026.”